Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks 
Asian Fund Managers Turn More Optimistic on Growth but Curb Equity Return Expectations: BofA Survey 
Dollar Holds Firm Ahead of Global Central Bank Decisions as Yen, Sterling and Euro React 
Japan Inflation Holds Firm in November as BOJ Nears Key Rate Hike Decision 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Kevin Hassett Says Inflation Is Below Target, Backs Trump’s Call for Rate Cuts 
Yen Near Lows as Markets Await Bank of Japan Rate Decision, Euro Slips After ECB Signals Caution 
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
